In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor

In our previous work, we replaced the TRM (tryptophan-rich motif) of T20 (Enfuvirtide) with fatty acid (C16) to obtain the novel lipopeptide LP-40, and LP-40 displayed enhanced antiviral activity. In this study, we investigated whether the C16 modification could enhance the high-resistance barrier o...

Full description

Bibliographic Details
Main Authors:	Yue Hu, Wenjiang Yu, Xiuzhu Geng, Yuanmei Zhu, Huihui Chong, Yuxian He
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	International Journal of Molecular Sciences
Subjects:	HIV-1 gp41 fusion inhibitor resistance LP-40 T20
Online Access:	https://www.mdpi.com/1422-0067/23/12/6638

Similar Items

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
by: Xiuzhu Geng, et al.
Published: (2019-07-01)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
by: Danwei Yu, et al.
Published: (2020-03-01)

Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
by: Adam S. Dingens, et al.
Published: (2019-05-01)

Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity
by: Li He, et al.
Published: (2022-12-01)

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile
by: Shan Su, et al.
Published: (2017-11-01)

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
by: Lin He, et al.
Published: (2023-05-01)

HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape
by: Ntombikhona F. Maphumulo, et al.
Published: (2024-04-01)

Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins
by: Garza Treviño Elsa N, et al.
Published: (2011-09-01)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
by: Asim K. Debnath, et al.
Published: (2013-01-01)

General complex Lp projection bodies and complex Lp mixed projection bodies
by: Cheng Manli, et al.
Published: (2022-04-01)

Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail
by: Takeo eKuwata, et al.
Published: (2013-05-01)

The Lp chord Minkowski problem
by: Xi Dongmeng, et al.
Published: (2023-01-01)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
by: Xinling Wang, et al.
Published: (2021-03-01)

Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent
by: Blandine Noailly, et al.
Published: (2022-06-01)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
by: Qianqian Qi, et al.
Published: (2017-01-01)

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile
by: Wei Xu, et al.
Published: (2022-03-01)

Strongly Lipschitz (ℓp ,ℓq)-factorable mappings
by: Dahmane Achour, et al.
Published: (2024-04-01)

A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life
by: Shan Su, et al.
Published: (2019-03-01)

Anti-HIV lectins and current delivery strategies
by: Fohona S. Coulibaly, et al.
Published: (2018-03-01)

HIV Transmembrane Glycoprotein Conserved Domains and Genetic Markers Across HIV-1 and HIV-2 Variants
by: Ana Valadés-Alcaraz, et al.
Published: (2022-05-01)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
by: Zheng Yang, et al.
Published: (2018-11-01)

Novel Binding Partners for CCT and PhLP1 Suggest a Common Folding Mechanism for WD40 Proteins with a 7-Bladed Beta-Propeller Structure
by: Wai Shun Mak, et al.
Published: (2021-10-01)

Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
by: Sonali Pechlivanis, et al.
Published: (2020-03-01)

Lp estimates for maximal functions along surfaces of revolution on product spaces
by: Ali Mohammed, et al.
Published: (2019-11-01)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
by: Danwei Yu, et al.
Published: (2021-01-01)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
by: Jing Pu, et al.
Published: (2021-01-01)

HIV-1 Entry, Inhibitors, and Resistance
by: Michael A. Lobritz, et al.
Published: (2010-04-01)

Prevalence of antibodies against an immunodominant region of the HIV-1 envelope glycoprotein gp41 in sera from HIV-1 infected individuals in Brazil
by: Vera Bongertz, et al.
Published: (1994-09-01)

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
by: Cunyat Francesc, et al.
Published: (2012-02-01)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
by: Yue Chen, et al.
Published: (2022-12-01)

Host and Viral Factors in HIV-Mediated Bystander Apoptosis
by: Himanshu Garg, et al.
Published: (2017-08-01)

HIV-1 Induced Bystander Apoptosis
by: Anjali Joshi, et al.
Published: (2012-11-01)

NUMERICAL ANALYSIS OF ADAPTIVE CONTROL IN LP TURBINES
by: PIOTR LAMPART, et al.
Published: (2005-04-01)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
by: Yuanmei Zhu, et al.
Published: (2022-12-01)

Lp-approximation for Shepard operators(Shepard算子的Lp-逼近)
by: XIAOWei(肖伟), et al.
Published: (2000-07-01)

On the Tits–Weiss conjecture and the Kneser–Tits conjecture for $\mathrm {E}^{78}_{7,1}$ and $\mathrm {E}^{78}_{8,2}$ (With an Appendix by R. M. Weiss)
by: Seidon Alsaody, et al.
Published: (2021-01-01)

Lp-potentials on infinite networks
by: Abodayeh Kamaleldin, et al.
Published: (2017-10-01)

Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1
by: Grant Klug, et al.
Published: (2023-04-01)

HIV-1 Envelope Glycoprotein Trafficking and Viral Transmission
by: Melissa Victoria Fernandez, et al.
Published: (2020-06-01)

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
by: Huan Liu, et al.
Published: (2018-04-01)